MARAVAI LIFESCIENCES HLDGS-A (MRVI)
US56600D1072 - Common Stock
MRVI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 59 industry peers in the Life Sciences Tools & Services industry. MRVI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRVI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year MRVI was profitable.
MRVI had a positive operating cash flow in the past year.
In multiple years MRVI reported negative net income over the last 5 years.
MRVI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MRVI's Return On Assets of -8.00% is in line compared to the rest of the industry. MRVI outperforms 49.15% of its industry peers.
MRVI's Return On Equity of -28.57% is on the low side compared to the rest of the industry. MRVI is outperformed by 62.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -28.57% | ||
| ROIC | N/A |
ROA(3y)3.71%
ROA(5y)3.14%
ROE(3y)23.17%
ROE(5y)30.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 48.50%, MRVI is in line with its industry, outperforming 52.54% of the companies in the same industry.
In the last couple of years the Gross Margin of MRVI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.3%
GM growth 5Y-0.98%
2. Health
2.1 Basic Checks
MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRVI has been reduced compared to 1 year ago.
MRVI has less shares outstanding than it did 5 years ago.
MRVI has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 1.94 indicates that MRVI is not a great score, but indicates only limited risk for bankruptcy at the moment.
MRVI has a Altman-Z score (1.94) which is comparable to the rest of the industry.
MRVI has a debt to FCF ratio of 9.18. This is a negative value and a sign of low solvency as MRVI would need 9.18 years to pay back of all of its debts.
MRVI's Debt to FCF ratio of 9.18 is in line compared to the rest of the industry. MRVI outperforms 59.32% of its industry peers.
MRVI has a Debt/Equity ratio of 1.32. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.32, MRVI is doing worse than 83.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.32 | ||
| Debt/FCF | 9.18 | ||
| Altman-Z | 1.94 |
ROIC/WACCN/A
WACC12.19%
2.3 Liquidity
A Current Ratio of 8.00 indicates that MRVI has no problem at all paying its short term obligations.
MRVI's Current ratio of 8.00 is amongst the best of the industry. MRVI outperforms 88.14% of its industry peers.
A Quick Ratio of 7.41 indicates that MRVI has no problem at all paying its short term obligations.
MRVI has a better Quick ratio (7.41) than 88.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8 | ||
| Quick Ratio | 7.41 |
3. Growth
3.1 Past
MRVI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -98.33%.
The Revenue for MRVI has decreased by -67.28% in the past year. This is quite bad
MRVI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.47% yearly.
EPS 1Y (TTM)-98.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-97.14%
Revenue 1Y (TTM)-67.28%
Revenue growth 3Y0.57%
Revenue growth 5Y18.47%
Revenue growth Q2Q-63.78%
3.2 Future
MRVI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 70.75% yearly.
Based on estimates for the next years, MRVI will show a small growth in Revenue. The Revenue will grow by 7.43% on average per year.
EPS Next Y-161.81%
EPS Next 2Y27.99%
EPS Next 3Y55.22%
EPS Next 5Y70.75%
Revenue Next Year-2.57%
Revenue Next 2Y3.49%
Revenue Next 3Y7.43%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 265.17, the valuation of MRVI can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of MRVI is on the same level as its industry peers.
MRVI's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.95.
The Forward Price/Earnings Ratio is negative for MRVI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 265.17 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MRVI is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, MRVI is valued a bit cheaper than 79.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 32.96 | ||
| EV/EBITDA | 121.73 |
4.3 Compensation for Growth
A more expensive valuation may be justified as MRVI's earnings are expected to grow with 55.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.99%
EPS Next 3Y55.22%
5. Dividend
5.1 Amount
No dividends for MRVI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MARAVAI LIFESCIENCES HLDGS-A
NASDAQ:MRVI (4/23/2024, 9:27:01 AM)
7.955
+0.59 (+7.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.00B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 265.17 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -28.57% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.32 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8 | ||
| Quick Ratio | 7.41 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-98.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-161.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-67.28%
Revenue growth 3Y0.57%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y